Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …

Introduction Meningitis is the most severe manifestation of tuberculosis, resulting in death or
disability in over 50% of those affected, with even higher morbidity and mortality among …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

The emergence and spread of resistant tuberculosis (TB) pose a threat to public health, so it
is necessary to diagnose the drug-resistant forms in a clinically short time frame and closely …

Essential components of public health include strengthening the surveillance of infectious
diseases and developing early detection and prevention policies. This is particularly …

Pyrazinamide (PZA) is widely used to treat drug-sensitive or multidrug resistance
tuberculosis. However, conventional PZA susceptibility tests of clinical isolates are rather …

Background Detection of pyrazinamide (PZA) resistance in Mycobacterium tuberculosis (TB)
patients is critical, especially in dealing with multidrug-resistant Mycobacterium tuberculosis …

Pyrazinamide remains the only drug in the tuberculosis pharmacopeia to drastically shorten
first-line therapy from nine to six months. Due to its unparalleled ability to sterilize non …

Background In this study, we utilized whole genome sequencing (WGS) of clinical extremely
drug-resistant tuberculosis (EDR-TB) strains collected during 2014–2020 in Beijing to detect …

This paper investigates different approaches for causal estimation under multiple concurrent
medications. Our parameter of interest is the marginal mean counterfactual outcome under …